5-IAI

From Wikipedia, the free encyclopedia
Jump to: navigation, search
"NRG-5" redirects here. For the compact food biscuit used for disaster relief, see BP-5 Compact Food.
5-IAI
5-iodo-2-aminoindane.svg
Clinical data
Pregnancy
category
  •  ?
Routes of
administration
Oral, Insufflated, Rectal
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
Formula C9H10IN
Molar mass 259.087 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

5-Iodo-2-aminoindane (5-IAI) is a drug which acts as a releasing agent of serotonin, norepinephrine, and dopamine.[1] It was developed in the 1990s by a team led by David E. Nichols at Purdue University.[2] 5-IAI fully substitutes for MDMA in rodents and is a putative entactogen in humans.[2] Unlike related aminoindane derivatives like MDAI and MMAI, 5-IAI causes some serotonergic neurotoxicity in rats, but is substantially less toxic than its corresponding amphetamine homologue pIA, with the damage observed barely reaching statistical significance.[1]

References[edit]

  1. ^ a b Johnson MP, Conarty PF, Nichols DE (July 1991). "[3H]monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues". European Journal of Pharmacology. 200 (1): 9–16. doi:10.1016/0014-2999(91)90659-E. PMID 1685125. 
  2. ^ a b Nichols DE, Johnson MP, Oberlender R (January 1991). "5-Iodo-2-aminoindan, a nonneurotoxic analogue of p-iodoamphetamine". Pharmacology, Biochemistry, and Behavior. 38 (1): 135–9. doi:10.1016/0091-3057(91)90601-W. PMID 1826785.